Department of Family Medicine, Federal Medical Centre, Murtala Mohammed Way (Jibia Bypass), P. M. B: 2121, Katsina, Nigeria.
Nigeria Field Epidemiology and Laboratory Training Programme, Abuja, Nigeria.
BMC Infect Dis. 2021 Oct 2;21(1):1031. doi: 10.1186/s12879-021-06722-3.
Human Immuno-Deficiency Virus (HIV) remains one of the world's significant public health challenges. Viral suppression is the key indicator for treatment success in People living with HIV (PLHIV). We determined the level of viral suppression, and its associated factors among PLHIV attending Federal Medical Centre Katsina (FMC Katsina), Nigeria.
This retrospective descriptive cross-sectional study was conducted on 913 HIV positive adults enrolled in care between January 2009 and December 2019. Information on socio-demographics, clinical, immunological, Viral load (VL), and other relevant parameters were extracted from the patients' care records. The primary outcome was the proportion of patients that achieved viral suppression. We also analyzed variables that were associated with VL suppression.
Of 913, records of 831 (91.0%) registered patients were analyzed. During the period, 751 (90.4%) achieved viral suppression, 427 (51.4%) had CD4 counts ≥ 500 and 477 (57.4%) were on HAART for ≥ 5 years. Majority, 793 (95.4%) were on first-line HAART regimen (Tenofovir-Lamivudine-Dolutegravir or Abacavir-Lamivudine-Dolutegravir), and 809 (97.4%) in the non-advanced stage (WHO stages 1 and 2). The median (interquartile range) of viral load was 20 (20-40) vs 19,989 (3311-110,340) cp/ml in virally suppressed, and unsuppressed respectively. Factors associated with viral suppression included being unemployed (Adjusted OR [AOR] 4.9, 95% CI 2.771, 8.539), educated (AOR 4.2, 95% CI 1.098, 16.223), having a baseline CD4 count ≥ 500 cells/µl (AOR 2.7, 95% CI 1.588, 4.625), and being on first line HAART regimen [AOR 7.0, 95% CI 3.220, 15.648].
Our study demonstrated a good viral suppression among PLHIV on HAART. Variables associated with viral suppression included unemployment, formal education, high baseline CD4 count, and first line HAART regimen.
人类免疫缺陷病毒（HIV）仍然是世界上重大的公共卫生挑战之一。病毒抑制是艾滋病毒感染者（PLHIV）治疗成功的关键指标。我们确定了在尼日利亚卡齐纳联邦医疗中心（FMC Katsina）接受治疗的 PLHIV 中的病毒抑制水平及其相关因素。
这是一项回顾性描述性横断面研究，对 2009 年 1 月至 2019 年 12 月期间登记的 913 名 HIV 阳性成年人进行了研究。从患者的护理记录中提取了社会人口统计学、临床、免疫、病毒载量（VL）和其他相关参数的信息。主要结局是达到病毒抑制的患者比例。我们还分析了与 VL 抑制相关的变量。
在 913 份记录中，分析了 831 份（91.0%）已注册患者的记录。在此期间，751 名（90.4%）达到了病毒抑制，427 名（51.4%）的 CD4 计数≥500，477 名（57.4%）接受了至少 5 年的高效抗逆转录病毒治疗（HAART）。大多数患者（793 名，95.4%）使用了一线 HAART 方案（替诺福韦-拉米夫定-多替拉韦或阿巴卡韦-拉米夫定-多替拉韦），809 名（97.4%）处于非晚期（世界卫生组织 1 期和 2 期）。病毒抑制组的病毒载量中位数（四分位距）为 20（20-40），未抑制组为 19，989（3311-110，340）cp/ml。与病毒抑制相关的因素包括失业（调整后的比值比[OR] 4.9，95%置信区间 2.771，8.539）、受教育程度（OR 4.2，95%置信区间 1.098，16.223）、基线 CD4 计数≥500 个细胞/µl（OR 2.7，95%置信区间 1.588，4.625）和一线 HAART 方案（OR 7.0，95%置信区间 3.220，15.648）。
我们的研究表明，接受高效抗逆转录病毒治疗的艾滋病毒感染者中病毒抑制良好。与病毒抑制相关的变量包括失业、正规教育、高基线 CD4 计数和一线 HAART 方案。
